dc.date.accessioned2022-01-18T19:26:50Z
dc.date.available2022-01-18T19:26:50Z
dc.date.created2022-01-18T19:26:50Z
dc.date.issued2012
dc.identifierhttps://hdl.handle.net/20.500.12866/10925
dc.identifierhttps://doi.org/10.1056/NEJMc1206959
dc.description.abstractNeurocysticercosis is endemic in most of the world, and it accounts for 2% of seizure cases in some areas of the United States.1 Extraparenchymal neurocysticercosis, discussed in the Case Record involving a patient with this disease (May 17 issue),2 is a slowly progressive disease that frequently involves the subarachnoid spinal space3 and can be fatal. It should be treated with surgery or antiparasitic agents until there are no remaining lesions.Although it is more sensitive than computed tomography, magnetic resonance imaging may not show all lesions. Monoclonal antibody–based antigen detection, briefly mentioned in the discussion of management . . .
dc.languageeng
dc.publisherMassachusetts Medical Society
dc.relationNew England Journal of Medicine
dc.relation1533-4406
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectNuclear Magnetic Resonance Imaging
dc.subjectDisease Severity
dc.subjectHeadache
dc.subjectAntiparasitic Agent
dc.subjectLetter
dc.subjectClinical Feature
dc.subjectComputer Assisted Tomography
dc.subjectAntibody Detection
dc.subjectImmunoassay
dc.subjectNeurocysticercosis
dc.subjectMonoclonal Antibody
dc.subjectDiplopia
dc.subjectTreatment Indication
dc.subjectNeurosurgery
dc.subjectPapilledema
dc.subjectSubarachnoid Space
dc.titleCase 15-2012: Diplopia, headaches, and papilledema
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución